Rathbones Group PLC Has $74.22 Million Position in DexCom, Inc. (NASDAQ:DXCM)

Key Points

• Rathbones Group PLC has reduced its stake in DexCom, Inc. by 6.2%, selling 72,144 shares, and now holds approximately 0.28% of the company valued at $74,222,000.
• Several hedge funds have increased their positions in DexCom, with Callan Family Office LLC boosting its investment by 141.4% during the first quarter.
• Analysts' ratings for DexCom are generally positive, with four analystssixteen analysts a buy rating, leading to an average target price of $99.89.

Rathbones Group PLC trimmed its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 6.2% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,086,869 shares of the medical device company's stock after selling 72,144 shares during the period. Rathbones Group PLC owned approximately 0.28% of DexCom worth $74,222,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Callan Family Office LLC increased its holdings in shares of DexCom by 141.4% in the first quarter. Callan Family Office LLC now owns 7,389 shares of the medical device company's stock valued at $505,000 after buying an additional 4,328 shares in the last quarter. Public Sector Pension Investment Board increased its holdings in shares of DexCom by 2.8% in the first quarter. Public Sector Pension Investment Board now owns 205,537 shares of the medical device company's stock valued at $14,036,000 after buying an additional 5,613 shares in the last quarter. Independent Advisor Alliance increased its holdings in shares of DexCom by 10.2% in the first quarter. Independent Advisor Alliance now owns 3,455 shares of the medical device company's stock valued at $236,000 after buying an additional 320 shares in the last quarter. Nuveen LLC bought a new position in shares of DexCom in the first quarter valued at $554,893,000. Finally, King Luther Capital Management Corp increased its holdings in shares of DexCom by 9.2% in the first quarter. King Luther Capital Management Corp now owns 242,650 shares of the medical device company's stock valued at $16,571,000 after buying an additional 20,518 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, EVP Sadie Stern sold 1,466 shares of the firm's stock in a transaction that occurred on Monday, July 28th. The shares were sold at an average price of $88.99, for a total value of $130,459.34. Following the transaction, the executive vice president directly owned 106,689 shares of the company's stock, valued at approximately $9,494,254.11. This trade represents a 1.36% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction on Monday, June 16th. The stock was sold at an average price of $82.80, for a total transaction of $41,400.00. Following the transaction, the executive vice president directly owned 95,102 shares in the company, valued at approximately $7,874,445.60. This represents a 0.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,656 shares of company stock valued at $2,412,191 over the last three months. 0.32% of the stock is owned by company insiders.

DexCom Stock Performance

NASDAQ:DXCM remained flat at $79.96 during mid-day trading on Thursday. 2,234,312 shares of the company traded hands, compared to its average volume of 3,910,198. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $93.25. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The firm has a market cap of $31.36 billion, a P/E ratio of 55.53, a price-to-earnings-growth ratio of 1.68 and a beta of 1.43. The company has a fifty day simple moving average of $83.17 and a two-hundred day simple moving average of $80.14.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.16 billion during the quarter, compared to analysts' expectations of $1.13 billion. During the same quarter in the previous year, the company posted $0.43 earnings per share. DexCom's quarterly revenue was up 15.2% compared to the same quarter last year. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have issued reports on DXCM. Citigroup reaffirmed a "buy" rating and issued a $102.00 price target (up previously from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Morgan Stanley boosted their target price on shares of DexCom from $82.00 to $89.00 and gave the company an "equal weight" rating in a research note on Tuesday, July 15th. Robert W. Baird cut their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. Barclays boosted their target price on shares of DexCom from $93.00 to $98.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 30th. Finally, Oppenheimer boosted their target price on shares of DexCom from $95.00 to $102.00 and gave the company an "outperform" rating in a research note on Thursday, July 31st. Four analysts have rated the stock with a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, DexCom presently has an average rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.